The trend among pharmaceutical companies to develop selective drugs of high potency has pushed the industry to consider the potential of each hazardous ingredient to become airborne. Dustiness issues are not unique to the pharmaceutical industry, but are relevant to any industry where powdered materials are mixed, transferred and handled. Interest in dustiness is also driven by concerns for worker health, the potential for plant explosions and the prevention of product loss. Unlike other industries, the pharmaceutical industry is limited by the milligram quantity of powdered material available for testing during product development. These needs have led to the development of a bench-top dustiness tester that requires only 10 mg of powder and fully contains the generated aerosol. The powder is dispersed within a 5.7 liter glass chamber that contains a respirable mass sampler and a closed-face sampler to quantify the respirable and total dust that are generated with a given energy input. The tester distinguished differences in dustiness levels of five different powders. Finer powders were dustier, and the respirable dust percentage was always less than that for total dust. Four testers have been built and evaluated using pharmaceutical grade lactose. Dustiness measurements determined using all four testers were comparable. The pharmaceutical industry uses surrogates such as lactose to represent active compounds in tests that estimate the dust concentration likely to occur in a new manufacturing operation. Differences between the dustiness of the active compound and its surrogate challenge the relevance of the surrogate tests to represent true exposures in the workplace. The tester can determine the dustiness of both the active compound and its surrogate, and the resultant ratio can help to interpret dust concentrations from surrogate tests. Further, dustiness information may allow the pharmaceutical researcher to select powder formulations that present low airborne concentrations in the workplace.
[1]
S P Binks,et al.
Occupational toxicology and the control of exposure to pharmaceutical agents at work.
,
2003,
Occupational medicine.
[2]
D Leith,et al.
Experimental examination of factors that affect dust generation.
,
1991,
American Industrial Hygiene Association journal.
[3]
Frank Hamelmann,et al.
Methods of Estimating the Dustiness of Industrial Powders – A Review
,
2003
.
[4]
B D Naumann,et al.
Performance-based exposure control limits for pharmaceutical active ingredients.
,
1996,
American Industrial Hygiene Association journal.
[5]
L. C. Kenny,et al.
Characterization and modelling of a family of cyclone aerosol preseparators
,
1995
.
[6]
R. Agius,et al.
Occupational exposure limits for therapeutic substances.
,
1989,
The Annals of occupational hygiene.
[7]
G.Th. Visser.
A wind-tunnel study of the dust emissions from the continuous dumping of coal
,
1992
.
[8]
R. Heron,et al.
Health effects of exposure to active pharmaceutical ingredients (APIs).
,
2003,
Occupational medicine.
[9]
Mary Ann Grelinger,et al.
An Apparatus and Methodology for Predicting the Dustiness of Materials
,
1989
.
[10]
Brian Cawley,et al.
Bench-Top Apparatus to Examine Factors that Affect Dust Generation
,
1993
.
[11]
D. Stauber,et al.
Determination and control of the dusting potential of feed premixes
,
1984
.
[12]
G V McHattie,et al.
The derivation of occupational exposure limits in the pharmaceutical industry.
,
1988,
The Journal of the Society of Occupational Medicine.
[13]
D. Leith,et al.
PARTICLE SEPARATION MECHANISMS IN FLOW OF GRANULAR MATERIAL
,
1994
.
[14]
E. V. Sargent,et al.
Establishing airborne exposure control limits in the pharmaceutical industry.
,
1988,
American Industrial Hygiene Association journal.